SCHEMBL642961

SCHEMBL642961

COC(=O)CC1CCCN1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS P14324 2/20 0.40
CHRNB4 P30926 2/20 0.38
CHRNA3 P32297 2/20 0.38
DRD2 P14416 2/20 0.37
DRD3 P35462 2/20 0.37
CYP2D6 P10635 2/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
TP53 P04637 1/20 0.35
CYP1A2 P05177 1/20 0.35
TSHR P16473 1/20 0.35
KMT2A Q03164 1/20 0.35
MLNR O43193 1/20 0.35
ABCB11 O95342 1/20 0.35
EGFR P00533 1/20 0.35
FYN P06241 1/20 0.35
CHRM2 P08172 1/20 0.35
CHRM4 P08173 1/20 0.35
HTR1A P08908 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1584792 1.00 FDPS (0.40) FDPSCHRNB4CHRNA3DRD2DRD3
SCHEMBL3669595 1.00 FDPS (0.40) FDPSCHRNB4CHRNA3DRD2DRD3
Hydrochloric Acid SCHEMBL3669594 0.98 FDPS (0.39) FDPSCHRNB4CHRNA3DRD2DRD3
Hydrochloric Acid SCHEMBL617456 0.98 FDPS (0.39) FDPSCHRNB4CHRNA3DRD2DRD3
Hydrochloric Acid SCHEMBL617457 0.98 FDPS (0.39) FDPSCHRNB4CHRNA3DRD2DRD3
SCHEMBL19987369 0.94 FDPS (0.46) FDPSCYP2D6MEN1ALDH1A1LMNA
SCHEMBL12481120 0.94 FDPS (0.46) FDPSCYP2D6MEN1ALDH1A1LMNA
SCHEMBL645913 0.94 FDPS (0.46) FDPSCYP2D6MEN1ALDH1A1LMNA
Hydrochloric Acid SCHEMBL645912 0.93 FDPS (0.45) FDPSCYP2D6MEN1ALDH1A1LMNA
Hydrochloric Acid SCHEMBL7301628 0.93 FDPS (0.45) FDPSCYP2D6MEN1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12371428-B2 Pyridone compounds and methods of use EXELIXIS, INC. (US) 2025-07-29 US disclosed
CN-119955463-A Heat-conducting adhesive composition and preparation method thereof 江苏欧跃环保科技有限公司 2025-05-09 CN disclosed
US-11708347-B2 Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2023-07-25 US disclosed
US-11708347-B2 Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2023-07-25 US disclosed
CN-116354932-A Pyrimidine derivative, preparation method and application thereof 海思科医药集团股份有限公司 2023-06-30 CN disclosed
WO-2023009585-A2 TRANSTHYRETIN STABILIZING COMPOUNDS PROTEGO BIOPHARMA, INC. (US) 2023-02-02 WO disclosed
US-20220315579-A1 PYRIDONE COMPOUNDS AND METHODS OF USE EXELIXIS, INC. 2022-10-06 US disclosed
CN-115093355-A Preparation method of pyrrole ester compound 河南农业大学 2022-09-23 CN disclosed
CN-112812113-B Immunomodulatory compounds, compositions and uses thereof 杭州和正医药有限公司 2022-09-20 CN disclosed
EP-4034532-A1 PYRIDONE COMPOUNDS AND METHODS OF USE IN THE MODULATION OF A PROTEIN KINASE Exelixis, Inc. (US) 2022-08-03 EP disclosed
US-20110082165-A1 PYRROLIDINE GPR40 MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2011-04-07 US disclosed
WO-2010144571-A1 HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF SEPRACOR INC. (US) 2010-12-16 WO disclosed
WO-2010144571-A1 HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF SEPRACOR INC. (US) 2010-12-16 WO disclosed
US-20090291938-A1 POLO-LIKE KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-26 US disclosed
WO-2009067547-A1 POLO-LIKE KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-05-28 WO disclosed
US-20080312231-A1 Substituted Sulfonamide Compounds GRUENENTHAL GMBH (DE) 2008-12-18 US disclosed
EP-1919913-A2 P38 MAP KINASE INHIBITORS AND METHODS FOR USING THE SAME F.HOFFMANN-LA ROCHE AG (CH) 2008-05-14 EP disclosed
WO-2007023110-A2 P38 MAP KINASE INHIBITORS AND METHODS FOR USING THE SAME F. HOFFMANN-LA ROCHE AG (CH) 2007-03-01 WO disclosed
US-6147087-A SELECTIVE POTASSIUM CHANNEL MODULATORS, IN PARTICULAR FOR THE TREATMENT OF THE CENTRAL NERVOUS SYSTEM BAYER AKTIENGESELLSCHAFT (DE) 2000-11-14 US disclosed
US-5990121-A SUCH AS METHYL 6-(3-NITROPHENYL)-7-OXO-1,2,3,4,6,7,8,9,10-NONAHYDROPYRIDO(1,2-A)QUINOLINE-5-CARBOXYLATE; USEFUL AS POTASSIUM CHANNEL MODULATORS FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS DEMENTIA BAYER AKTIENGESELLSCHAFT (DE) 1999-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12371428-B2 Pyridone compounds and methods of use PDXK, PLK2, MAP4K2 FDPS 837/4885CHRNB4 1921/4885CHRNA3 1971/4885
US-20080312231-A1 Substituted Sulfonamide Compounds SULT2A1, SULT1A1, SCN1A FDPS 350/4885CHRNB4 4114/4885CHRNA3 3803/4885
US-20090291938-A1 POLO-LIKE KINASE INHIBITORS PLK1, PLK2, POLK FDPS 2640/4885CHRNB4 4495/4885CHRNA3 4587/4885
US-20220315579-A1 PYRIDONE COMPOUNDS AND METHODS OF USE PDXK, PLK2, MAP4K2 FDPS 837/4885CHRNB4 1921/4885CHRNA3 1971/4885
US-11708347-B2 Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors C9, C5, C1QBP FDPS 71/4885CHRNB4 4776/4885CHRNA3 4817/4885
US-20110082165-A1 PYRROLIDINE GPR40 MODULATORS GPR55, GPR65, GPR27 FDPS 2637/4885CHRNB4 515/4885CHRNA3 602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.